EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5FU bolus and infusion, and emcitabine



Multicenter phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5FU bolus and infusion, and emcitabine



Gastroenterology 116(4 PART 2): A417, April




(PDF 0-2 workdays service: $29.90)

Accession: 035349865

Download citation: RISBibTeXText



Related references

Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients. Anticancer Research 34(4): 2029-2034, 2014

Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer: A multicenter phase II study. Cancer (Philadelphia) 72(7): 2107-2111, 1993

A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study. Investigational New Drugs 22(3): 335-341, 2004

S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study. Oncologist 19(11): 1133-1134, 2015

Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. Journal of Clinical Oncology 22(23): 4753-4761, 2004

Phase II Trial of Gemcitabine, UFT-E, Leucovorin Combination Chemotherapy in Advanced Pancreatic Adenocarcinoma. Cancer Research and Treatment 34(2): 111-116, 2002

A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncologica 46(3): 336-341, 2007

Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma. Journal of ChemoTherapy 19(6): 724-730, 2008

Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies. Cancer ChemoTherapy and Pharmacology 32(3): 215-220, 1993

A phase II study of oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced or metastatic gastric cancer. Journal of Clinical Oncology 24(18_suppl): 14052-14052, 2016

A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Japanese Journal of Clinical Oncology 37(10): 744-749, 2007

Irinotecan in combination with infusional 5-fluorouracil and leucovorin as first-line treatment in patients with advanced colorectal cancer A multicenter phase II study. American Journal of Clinical Oncology 25(1): 65-70, February, 2002

Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. American Journal of Clinical Oncology 33(5): 461-464, 2010

Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Anti-Cancer Drugs 19(3): 283-288, 2008